WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Florida Hospital Association
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Medical
Ebanga | December 29, 2020
Ridgeback Biotherapeutics LP ("Ridgeback"), a biotechnology organization experienced in antiviral drug improvement, reported today that the U.S. Food and Drug Administration ("FDA") approved EbangaTM for the treatment of Ebola. Ebanga is presently affirmed for treatment of disease brought about by Zaire ebolavirus in grown-up and pediatric patients. Ebanga is the only FDA endorsed, single infusion Ebola treatment which is accessible in a lyophilized structure.<...
Industrial Impact
Quantum Genomics | December 06, 2021
Quantum Genomics, a biopharmaceutical company specializing in the development of first-in-class drugs directly targeting the brain to treat complex/resistant hypertension, has announced the signing of an exclusive license and production agreement with Julphar to market and produce firibastat in the Middle East, all African countries, Commonwealth of Independent States and Turkey. A pharmaceutical company based in the United Arab Emirates and leader in the MENA region, Julphar will...
Cell and Gene Therapy, Industrial Impact
Evaxion | February 10, 2023
Evaxion Biotech A/S, a clinical-phase biotech company specializing in enhancing AI-powered immunotherapies, and Pantherna Therapeutics GmbH, a biopharmaceutical company developing enhanced nanoparticle solutions for delivering and expressing mRNA therapeutics, announced a preclinical proof of concept for the combination of their key technologies. Using Pantherna's unique lipid nanoparticle mRNA technology (PTXLNP®, PTXmRNA®), tumor neoantigens discovered by Evaxion...
Illumina | May 27, 2022
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the addition of a companion diagnostic (CDx) indication to its CE-marked in vitro diagnostic TruSight™ Oncology (TSO) Comprehensive (EU) test. This single test kit, recently launched across Europe, assesses multiple tumor genes and biomarkers to reveal the specific molecular profile of a patient's cancer. The CDx pan-cancer indication will allow identification of cancer patien...
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE